{
    "clinical_study": {
        "@rank": "25209", 
        "arm_group": [
            {
                "arm_group_label": "Low dose TBI-1201 with pre-treatment 1", 
                "arm_group_type": "Experimental", 
                "description": "TBI-1201(5*10^8) single-dose administration with pre-treatment of cyclophosphamide alone."
            }, 
            {
                "arm_group_label": "High dose TBI-1201 with pre-treatment 1", 
                "arm_group_type": "Experimental", 
                "description": "TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide alone."
            }, 
            {
                "arm_group_label": "High dose TBI-1201 with pre-treatment 2", 
                "arm_group_type": "Experimental", 
                "description": "TBI-1201(5*10^9) single-dose administration with pre-treatment of cyclophosphamide and fludarabine."
            }, 
            {
                "arm_group_label": "TBI-1201 with pre-treatment 1 or 2", 
                "arm_group_type": "Experimental", 
                "description": "Arm1, 2 or 3, which is considered as optimal."
            }
        ], 
        "brief_summary": {
            "textblock": "Following pre-treatment with cyclophosphamide and/or fludarabine, MAGE-A4-specific TCR gene\n      transduced T lymphocytes are transferred to the patients with MAGE-A4-expressing solid\n      tumors."
        }, 
        "brief_title": "Investigator Initiated Phase 1 Study of TBI-1201", 
        "condition": "Solid Tumors", 
        "detailed_description": {
            "textblock": "Following pre-treatment with cyclophosphamide alone or in combination with fludarabine,\n      MAGE-A4-specific TCR gene transduced T lymphocytes are transferred to HLA-A*24:02 positive\n      patients with solid tumors which are 1) unresectable, refractory to standard therapy\n      (chemotherapy, radiotherapy, etc), metastatic or recurrent, and 2) MAGE-A4-expressing.  The\n      primary objective is to evaluate the safety and in vivo kinetics, and the secondary is to\n      evaluate clinical effect."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically or cytologically confirmed solid tumors\n\n          2. Stage \u2162 or \u2163 (TNM) solid tumor, which is unresectable , refractory to standard\n             therapy (chemotherapy, radiotherapy, etc) , metastatic or recurrent\n\n          3. HLA-A*24:02 positive\n\n          4. MAGE-A4-expression by PCR or immunohistochemistry\n\n          5. Measurable disease\n\n          6. ECOG Performance Status, 0 or 1\n\n          7. Age >20 years on consent\n\n          8. All previous surgery, chemotherapy and radiotherapy must be completed at least 4\n             weeks when lymphocytes are collected for gene transfer.\n\n          9. Life expectancy >12 weeks after consent\n\n         10. No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc)\n             and meet the following lab value criteria:\n\n               -  WBC            > 2,500/\u03bcL\n\n               -  Hemoglobin             > 8.0g/dL\n\n               -  Platelets                > 75,000/\u03bcL\n\n               -  T. bilirubin             < 1.5 x ULN\n\n               -  AST(GOT)\u3001ALT(GPT)   < 3.0 x ULN\n\n               -  Creatinine               < 1.5 x ULN\n\n         11. Ability to understand the study contents and to give a written consent at his/her\n             free will.\n\n        Exclusion Criteria:\n\n          1. The following serious complications are excluded from the study;\n\n               -  Unstable angina, cardiac infarction, or heart failure\n\n               -  Uncontrolled diabetes or hypertension\n\n               -  Active infection\n\n               -  Obvious interstitial pneumonia or lung fibrosis by chest X-ray\n\n               -  Autoimmune disease\n\n          2. Serious hypersensitivity\n\n          3. Tumor cell invasion into CNS\n\n          4. Active multiple cancer\n\n          5. Positive for HBs antigen/antibody, HBc antibody, or HCV antibody, and virus DNA\n             observed in serum, except for HBs antibody positive case who had vaccine injection\n             before.\n\n          6. Positive for antibodies against HIV or HTLV-1\n\n          7. Left Ventricular Ejection Fraction (LVEF): < 50\uff05\n\n          8. Percutaneous Oxygen saturation: < 94\uff05\n\n          9. History of hypersensitivity reactions to bovine, murine, or equine derived\n             substances.\n\n         10. Under the treatment with chemotherapy and radiotherapy.\n\n         11. Psychological disorder or drug dependency which may have impact on the consent.\n\n         12. Pregnant or lactating females, female and male patients who cannot agree to practice\n             the adequate birth control after the consent during the study\n\n         13. Clinically significant systemic illness that in the judgment of the PI or\n             sub-investigator would compromise the patient's ability to tolerate protocol therapy\n             or significantly increase the risk of complications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096614", 
            "org_study_id": "1201-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low dose TBI-1201 with pre-treatment 1", 
                    "High dose TBI-1201 with pre-treatment 1", 
                    "High dose TBI-1201 with pre-treatment 2", 
                    "TBI-1201 with pre-treatment 1 or 2"
                ], 
                "description": "TBI-1201(5*10^8 or 5*10^9) is administered.", 
                "intervention_name": "TBI-1201", 
                "intervention_type": "Drug", 
                "other_name": "MAGE-A4-specific TCR gene transduced T lymphocytes"
            }, 
            {
                "arm_group_label": [
                    "Low dose TBI-1201 with pre-treatment 1", 
                    "High dose TBI-1201 with pre-treatment 1", 
                    "High dose TBI-1201 with pre-treatment 2", 
                    "TBI-1201 with pre-treatment 1 or 2"
                ], 
                "description": "Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201", 
                "intervention_name": "Cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": "Endoxan"
            }, 
            {
                "arm_group_label": [
                    "High dose TBI-1201 with pre-treatment 2", 
                    "TBI-1201 with pre-treatment 1 or 2"
                ], 
                "description": "Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.", 
                "intervention_name": "Fludarabine", 
                "intervention_type": "Drug", 
                "other_name": "Fludara"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Fludarabine monophosphate", 
                "Fludarabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adoptive cell transfer", 
            "Cell therapy", 
            "Immunotherapy", 
            "MAGE-A4", 
            "Esophageal cancer", 
            "Melanoma", 
            "Head and neck cancer", 
            "Ovarian cancer", 
            "TCR gene therapy"
        ], 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "contact": {
                "last_name": "Yasuyuki Ota, Ph.D."
            }, 
            "contact_backup": {
                "last_name": "Chisato Minamide, RN"
            }, 
            "facility": {
                "address": {
                    "city": "Tsu", 
                    "country": "Japan", 
                    "state": "Mie"
                }, 
                "name": "Mie University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "Multi-center, Investigator Initiated Phase 1 Study of MAGE-A4 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors", 
        "overall_contact": {
            "email": "miyamoto@fiverings.co.jp", 
            "last_name": "Hiroshi Miyamoto", 
            "phone": "+81-6-6358-7004"
        }, 
        "overall_official": [
            {
                "affiliation": "Department of Immuno-Gene Therapy, Mie University, graduate School of Medicine", 
                "last_name": "Hiroshi Shiku, M.D., Ph.D.", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Mie University Hospital", 
                "last_name": "Shinichi Kageyama, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Confirm the toxicity profile, which is measured by the degree of grade and seriousness, duration, causality, classification, etc. of the adverse events.", 
                "measure": "Incidence and grade of adverse events (CTCAE)", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Confirm no replication competent retrovirus observed", 
                "measure": "Appearance of replication competent retrovirus by PCR", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Confirm no clonality is observed", 
                "measure": "Appearance of clonality by LAM-PCR", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Evaluate persistence and expansion of transferred TBI-1201", 
                "measure": "Kinetics of TBI-1201 in blood by realtime-PCR and flow cytometry", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096614"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mie University", 
            "investigator_full_name": "Shinichi Kageyama", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mie University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Takara Bio Inc.", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Shionogi", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Fiverings Co., Ltd.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Statcom Co. Ltd.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Mie University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}